Repatha Patient Assistance for Low-Income Patients: How to Get Evolocumab Affordable

Why Repatha Costs So Much and Why Assistance Matters

Evolocumab belongs to the PCSK9 inhibitor class, a category of fully human monoclonal antibodies that block proprotein convertase subtilisin/kexin type 9 to dramatically lower LDL cholesterol. The drug arrived on the U.S. market in 2015 with an annual wholesale acquisition cost exceeding $14,000. Amgen reduced the list price by roughly 60% in 2018, bringing it closer to $5,850 per year, yet out-of-pocket exposure remains steep for patients without strong prescription coverage [1].

A 2019 analysis published in JAMA Cardiology found that high out-of-pocket costs for PCSK9 inhibitors were associated with a 32% higher rate of treatment discontinuation compared to patients paying less than $50 per month [2]. That discontinuation carries real consequences. The FOURIER trial (N=27,564) demonstrated that evolocumab 140 mg every two weeks reduced LDL cholesterol by 59% from baseline and lowered the composite primary endpoint of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization by 15% (HR 0.85 to 95% CI 0.79-0.92, P<0.001) over a median follow-up of 2.2 years [3]. Patients who stop therapy lose that protection.

The gap between clinical benefit and affordability is the core problem. Assistance programs exist precisely to close it.

The Amgen Safety Net Foundation: Free Repatha for Qualifying Patients

The most direct route to zero-cost Repatha is the Amgen Safety Net Foundation, the manufacturer's independent patient assistance program. This program supplies Repatha at no charge to patients who meet three criteria: they lack adequate insurance coverage for the drug, their household income falls at or below 400% of the federal poverty level (roughly $62,400 for a single individual in 2025, adjusted annually), and they have a valid U.S. prescription.

Applications require a signed enrollment form from both the patient and prescriber, proof of income (tax return, pay stubs, or a signed attestation), and documentation of insurance status. Approval typically takes 2 to 4 weeks. Once approved, the foundation ships Repatha directly to the patient or their physician's office at no cost, and enrollment renews annually with income re-verification.

Dr. Seth Baum, a preventive cardiologist and past president of the American Society for Preventive Cardiology, has stated: "No patient with a clinical indication for a PCSK9 inhibitor should go untreated because of cost. The manufacturer programs are underutilized, and prescribers need to initiate the paperwork proactively."

Patients who are uninsured, enrolled in a plan that explicitly excludes Repatha, or facing a coverage denial after appeal may all qualify. Medicare and Medicaid beneficiaries are generally ineligible for manufacturer-funded programs due to federal anti-kickback statutes, but separate pathways exist for those populations (discussed below).

The Repatha Copay Card: Reducing Commercially Insured Costs

For patients with commercial (private) insurance that covers Repatha, the Amgen copay assistance program offers a copay card that can reduce the monthly out-of-pocket cost to as little as $5. The card covers the difference between the patient's copay or coinsurance and that $5 floor, up to an annual maximum benefit that Amgen sets each calendar year (historically $6,000 to $10,000 per year).

Eligibility requires commercial insurance. Patients covered by Medicare, Medicaid, TRICARE, or any other federal or state government-funded program cannot use the copay card. The card activates at the pharmacy and applies automatically at the point of sale once enrolled. Enrollment is available online, by phone, or through the prescriber's office.

One practical consideration: patients with high-deductible health plans may find that the copay card does not count toward their deductible. Some insurers have implemented accumulator adjuster programs that prevent manufacturer copay assistance from applying to deductible or out-of-pocket maximum calculations [4]. Check your plan's benefit design before assuming the copay card will accelerate your deductible.

Navigating Insurance Coverage and Prior Authorization

Nearly every commercial and government payer requires prior authorization before covering Repatha. The prior authorization process for PCSK9 inhibitors typically demands documentation of three elements: a confirmed diagnosis (HeFH, HoFH, or clinical ASCVD), failure of or intolerance to maximally tolerated statin therapy, and an LDL level that remains above a defined threshold despite treatment.

The 2018 American College of Cardiology/American Heart Association (ACC/AHA) cholesterol guidelines identify specific patient groups most likely to benefit from PCSK9 inhibitor therapy. These include patients with clinical ASCVD and LDL persistently at or above 70 mg/dL on maximally tolerated statins, and patients with HeFH and LDL at or above 100 mg/dL despite high-intensity statin plus ezetimibe [5]. Most insurers base their approval criteria on these thresholds.

A 2020 study in Circulation: Cardiovascular Quality and Outcomes reported that initial prior authorization denial rates for PCSK9 inhibitors ranged from 50% to 80% depending on the payer, though appeal success rates exceeded 60% when prescribers submitted comprehensive clinical documentation [6]. The denial rate has decreased since 2020, partly because Amgen's list price reduction triggered broader formulary adoption, but prior authorization remains the single largest access barrier.

Tips for a successful prior authorization:

• Document every statin and ezetimibe trial with dates, doses, LDL responses, and reasons for discontinuation or dose limitation
• Include genetic testing results if familial hypercholesterolemia is suspected
• Attach lipid panel results before and after each therapy change
• Reference the ACC/AHA guideline recommendations by name
• Submit an appeal with a peer-to-peer review request if the initial authorization is denied

Medicare Coverage: Part D, Extra Help, and State Programs

Medicare Part D plans cover Repatha, but it typically sits on the specialty tier (Tier 5), which means coinsurance of 25% to 33% during the initial coverage phase. For a drug with a list price near $580 per month, that translates to $145 to $190 per month before reaching the catastrophic coverage threshold.

The Medicare Part D Extra Help program (also called the Low-Income Subsidy, or LIS) substantially reduces these costs for qualifying beneficiaries. Full Extra Help eliminates premiums and reduces copays to $4.50 for generic and $11.20 for brand-name drugs in 2025. Partial Extra Help reduces premiums and sets a sliding copay scale. Eligibility is based on income (below 150% of the federal poverty level) and assets [7].

As of 2025, the Inflation Reduction Act capped total out-of-pocket Part D spending at $2,000 per year for all Medicare beneficiaries. This cap applies to Repatha and means that even without Extra Help, a Medicare patient's total annual prescription drug out-of-pocket costs will not exceed $2,000 across all medications [8]. Medicare also allows beneficiaries to spread that $2,000 across monthly installments through the Medicare Prescription Payment Plan.

State Pharmaceutical Assistance Programs (SPAPs) offer an additional layer of support. States including New York (EPIC), Pennsylvania (PACE), and Connecticut (ConnPACE) maintain programs that wrap around Medicare Part D to further reduce out-of-pocket costs for low-income seniors. Eligibility varies by state.

Medicaid and Dual-Eligible Pathways

Medicaid covers Repatha in all 50 states, though formulary placement and prior authorization requirements vary by state Medicaid program and managed care organization. Medicaid copays for brand-name drugs are capped at nominal amounts (typically $1 to $4 per prescription for most beneficiaries) under federal law. Patients who are dually eligible for both Medicare and Medicaid receive the lowest cost-sharing tier available.

The primary barrier for Medicaid patients is not cost but access. Many state Medicaid programs apply strict step-therapy requirements, demanding documented failure of two or more lipid-lowering agents before approving a PCSK9 inhibitor. Some states also impose quantity limits or require specialist prescribing. A 2021 analysis in the Journal of the American Heart Association found that Medicaid-covered patients with ASCVD were 40% less likely to receive a PCSK9 inhibitor than commercially insured patients with the same diagnosis, driven largely by administrative access barriers rather than out-of-pocket costs [9].

Working with a cardiologist or lipid specialist who routinely manages these authorizations can significantly improve approval odds.

Specialty Pharmacy Programs and Alternate Access Routes

Repatha is classified as a specialty medication, meaning it is dispensed through specialty pharmacies rather than retail chains. Most insurance plans designate a preferred specialty pharmacy (Accredo, CVS Specialty, OptumRx Specialty, or Biologics by McKesson are among the largest). Using an out-of-network specialty pharmacy may result in higher cost-sharing or outright claim denial.

Several specialty pharmacies offer their own financial assistance coordination services. These pharmacy-based programs help patients identify and enroll in all available assistance, including the Amgen Safety Net Foundation, copay cards, state programs, and independent charitable foundations. The Patient Access Network Foundation (PAN Foundation) and the HealthWell Foundation are two independent nonprofits that have periodically offered grants for PCSK9 inhibitor copays, though fund availability fluctuates and waitlists are common [10].

A practical step: ask your specialty pharmacy's patient navigator to run a benefits investigation before your first fill. This investigation maps your exact cost-sharing, identifies applicable programs, and flags potential prior authorization issues before you are standing at the pharmacy counter.

Clinical Value Context: Why Access Matters Beyond Cost

The question of Repatha affordability is inseparable from the question of cardiovascular risk. The cost-effectiveness debate has shifted substantially since Amgen's 2018 price reduction. An updated analysis by the Institute for Clinical and Economic Review (ICER) in 2019 concluded that at the net price of approximately $5,850 per year, evolocumab approaches cost-effectiveness thresholds for patients with established ASCVD and LDL at or above 100 mg/dL despite maximally tolerated statin therapy [11].

In the FOURIER trial's extended follow-up (FOURIER-OLE), patients randomized to evolocumab for a median of 5 years showed a 15% reduction in cardiovascular death (HR 0.85 to 95% CI 0.73-0.98), with the survival curves continuing to separate over time [12]. This finding supports the concept that sustained LDL lowering accumulates benefit.

The American Heart Association's 2022 statement on health equity in cardiovascular care noted: "Financial barriers to guideline-directed medical therapy disproportionately affect Black and Hispanic patients, who carry higher ASCVD burden and face greater insurance coverage gaps" [13]. Ensuring equitable access to therapies like evolocumab is not merely a financial concern. It is a clinical equity issue.

Step-by-Step: Getting Repatha at the Lowest Possible Cost

The process differs by insurance status. Here is a straightforward pathway for each scenario.

Commercially insured patients: First, confirm that Repatha is on your plan's formulary and identify the tier. Submit a prior authorization with full documentation of statin failure or intolerance. Once approved, enroll in the Repatha copay card to reduce your copay to $5 per month. If your plan uses an accumulator adjuster, ask your insurer whether copay card funds count toward your deductible.

Uninsured or underinsured patients: Apply to the Amgen Safety Net Foundation. Gather proof of income and insurance status. Have your prescriber complete and submit the enrollment form. Expect 2 to 4 weeks for approval. If denied, contact Amgen's patient support line for reconsideration or explore independent charitable foundations like PAN or HealthWell.

Medicare beneficiaries: Verify Repatha coverage on your Part D plan using the Medicare Plan Finder at medicare.gov. Apply for Extra Help if your income is below 150% FPL. The $2,000 annual out-of-pocket cap under the Inflation Reduction Act provides a hard ceiling. Enroll in the Medicare Prescription Payment Plan to spread costs across 12 monthly installments. Check whether your state operates a pharmaceutical assistance program.

Medicaid beneficiaries: Copays will be minimal ($1 to $4), but prior authorization and step-therapy requirements may delay access. Work with a lipid specialist who can submit a thorough prior authorization and pursue peer-to-peer review if denied.

Across all pathways, keep records of every denial, appeal, and communication. Documentation is the single most effective tool for overcoming access barriers.